Deferiprone (tradenames include Ferriprox) is a drug that chelates iron and is used to treat thalassaemia major. It was first approved for use in treating [1 ] thalassaemia major in 1994 and had been licensed for use in [2 ] Europe and Asia for many years while awaiting approval in Canada and the United States. [1 ] On October 14, 2011, it was approved for use in the US under the FDA’s accelerated approval program. [3 ] [4 ]
Controversy [ edit ]
Deferiprone was at the center of a protracted struggle between
Nancy Olivieri, a Canadian haematologist and researcher, and the Hospital for Sick Children and pharmaceutical giant Apotex, that started in 1996 and delayed approval of the drug in North America. Dr. Olivieri's data suggested deferiprone leads to progressive [5 ] hepatic fibrosis. [6 ] [7 ]
See also [ edit ]
References [ edit ]
^ a b Savulescu J (2004). "Thalassaemia major: the murky story of deferiprone". BMJ 328 (7436): 358–9. doi: 10.1136/bmj.328.7436.358. PMC 341373. PMID 14962851. Full Text.
^ Staff, Cipla. Cipla's History
^ FDA NEWS RELEASE: FDA Approves Ferripox (deferiprone) to Treat Patients with Excess Iron in the Body, Oct. 14, 2011 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm275814.htm
^ Viens A, Savulescu J (2004). "Introduction to The Olivieri symposium.". J Med Ethics 30 (1): 1–7. doi: 10.1136/jme.2003.006577. PMC 1757126. PMID 14872065.
^ Brittenham G, Nathan D, Olivieri N, Porter J, Pippard M, Vichinsky E, Weatherall D (2003). "Deferiprone and hepatic fibrosis". Blood 101 (12): 5089–90; author reply 5090–1. doi: 10.1182/blood-2002-10-3173. PMID 12788794. Full Text.
^ Wanless I, Sweeney G, Dhillon A, Guido M, Piga A, Galanello R, Gamberini M, Schwartz E, Cohen A (2002). "Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia". Blood 100 (5): 1566–9. doi: 10.1182/blood-2002-01-0306. PMID 12176871. Full Text.